About Ascendis Pharma A/S
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. The Company's subsidiaries include Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma and Endocrinology Division A/S (Denmark).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ASND
- Previous Close: $28.24
- 50 Day Moving Average: $22.07
- 200 Day Moving Average: $19.93
- 52-Week Range: $11.92 - $29.69
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -11.82
- P/E Growth: -0.49
- Market Cap: $699.80M
- Beta: 0.22
- Net Margins: -1,158.57%
- Return on Equity: -65.92%
- Return on Assets: -58.86%
Companies Related to Ascendis Pharma A/S:
- Current Ratio: 6.52%
- Quick Ratio: 6.52%
What is Ascendis Pharma A/S's stock symbol?
Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."
Where is Ascendis Pharma A/S's stock going? Where will Ascendis Pharma A/S's stock price be in 2017?
3 equities research analysts have issued 12-month target prices for Ascendis Pharma A/S's stock. Their predictions range from $24.00 to $31.00. On average, they anticipate Ascendis Pharma A/S's share price to reach $27.67 in the next twelve months.
When will Ascendis Pharma A/S announce their earnings?
Ascendis Pharma A/S is scheduled to release their next quarterly earnings announcement on Wednesday, November, 30th 2016.
What are analysts saying about Ascendis Pharma A/S stock?
Here are some recent quotes from research analysts about Ascendis Pharma A/S stock:
According to Zacks Investment Research, "Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. " (2/16/2017)
Leerink Swann analysts commented, "We project that ASND’s cash position at YE16 will be ~ $180M and expect this will fund operations through completion of its TransCon Growth Hormone study in 2018." (12/1/2016)
Who owns Ascendis Pharma A/S stock?
Ascendis Pharma A/S's stock is owned by many different of institutional and retail investors. Top institutional shareholders include RA Capital Management, LLC (17.10%), FMR LLC (12.51%), Orbimed Advisors LLC (10.78%), Vivo Capital LLC (7.01%), Deerfield Management Co. (4.17%) and EcoR1 Capital LLC (3.87%).
Who sold Ascendis Pharma A/S stock? Who is selling Ascendis Pharma A/S stock?
Ascendis Pharma A/S's stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC.
Who bought Ascendis Pharma A/S stock? Who is buying Ascendis Pharma A/S stock?
Ascendis Pharma A/S's stock was bought by a variety of institutional investors in the last quarter, including Deerfield Management Co., EcoR1 Capital LLC, FMR LLC, Orbimed Advisors LLC, Eventide Asset Management LLC, Acuta Capital Partners LLC, Foresite Capital Management III LLC and Marshall Wace LLP.
How do I buy Ascendis Pharma A/S stock?
Shares of Ascendis Pharma A/S can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Ascendis Pharma A/S stock cost?
One share of Ascendis Pharma A/S stock can currently be purchased for approximately $27.67.